Mehdi Gasmi, PhD

More documents

Recommendations

Info

AAV by transfection-Conclusions‣Process OK for GMP- early stage (FBS)‣Multiple manipulations of CF10 : risk of microorg.contamination‣Process approved for clinical trials‣OK for applications that do not require large amounts ofvectors (retina, CNS…etc)‣Not compatible for applications like DMDlarge muscle tissue=> high titer, large volumes‣Need for a scalable system, compliant with cGMPConfidential
Baculovirus Technology‣rAAV production system developed in collaboration with R. Kotin(NIH)‣Non pathogenic insect virus that does not infect human cells‣Cell substrate (Sf9)•Non tumorigenic•Allows rAAV replication/production without helper virus•Robust growth in defined media•No fetal bovine serum requiredConfidenti
Page 1 and 2: Improvements towards the industrial
Page 3 and 4: AAV vectors in the clinic‣~30% pr
Page 5 and 6: Transfection for rAAV production at
Page 7: Transfection in suspension: lack of
Page 11 and 12: AAV -Bac systemSf9 MCB/WCBAmplifica
Page 13 and 14: vg titer (vg/mL)rAAV-Bac: YieldsRes
Page 15 and 16: Comparison rAAV transfection vs. rA
Page 17 and 18: Detailed presentation of Genethon

Mehdi Gasmi, PhD

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?